A novel assay to identify entry inhibitors that block binding of HIV-1 gp120 to CCR5. (Q40523804)

21 September 2017

title

A novel assay to identify entry inhibitors that block binding of HIV-1 gp120 to CCR5. (English)

1 reference

21 September 2017

Qian Zhao

1

1 reference

21 September 2017

Yuxian He

series ordinal

2

1 reference

21 September 2017

Gabriel Alespeiti

series ordinal

3

1 reference

21 September 2017

Asim Kumar Debnath

series ordinal

4

1 reference

21 September 2017

language of work or name

English

0 references

publication date

1 September 2004

1 reference

21 September 2017

1 reference

21 September 2017

volume

326

1 reference

21 September 2017

issue

2

1 reference

21 September 2017

page(s)

299-309

1 reference

A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity

21 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.06.022

Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.06.022

HIV-1 entry and how to block it.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.06.022

Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bis-azamacrocycles that inhibit HIV-1 and HIV-2 replication by antagonism of the chemokine receptor CXCR4

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.06.022

A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.06.022

Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.06.022

Binding of 2-aryl-4-(piperidin-1-yl)butanamines and 1,3,4-trisubstituted pyrrolidines to human CCR5: a molecular modeling-guided mutagenesis study of the binding pocket

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.06.022

Enfuvirtide (T-20): A Novel Human Immunodeficiency Virus Type 1 Fusion Inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.06.022

Core structure of gp41 from the HIV envelope glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.06.022

A simple screening system for anti-HIV drugs: syncytium formation assay using T-cell line tropic and macrophage tropic HIV env expressing cell lines--establishment and validation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.06.022

The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.06.022

Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.06.022

The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.06.022

Generation of Predictive Pharmacophore Models for CCR5 Antagonists: Study with Piperidine- and Piperazine-Based Compounds as a New Class of HIV-1 Entry Inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.06.022

Three-dimensional structure-activity analysis of a series of porphyrin derivatives with anti-HIV-1 activity targeted to the V3 loop of the gp120 envelope glycoprotein of the human immunodeficiency virus type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.06.022

Covalently crosslinked complexes of human immunodeficiency virus type 1 (HIV-1) gp120 and CD4 receptor elicit a neutralizing immune response that includes antibodies selective for primary virus isolates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.06.022

AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.06.022

A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.06.022

CD4-independent infection by HIV-2 is mediated by fusin/CXCR4.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.06.022

HIV's response to a CCR5 inhibitor: I'd rather tighten than switch!

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.06.022

Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 3: a proposed pharmacophore model for 1-[N-(methyl)-N-(phenylsulfonyl)amino]-2-(phenyl)-4-[4-(substituted)piperidin-1-yl]butanes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.06.022

Expression and characterization of a single-chain polypeptide analogue of the human immunodeficiency virus type 1 gp120-CD4 receptor complex

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.06.022

Envelope glycoproteins of HIV-1, HIV-2, and SIV purified with Galanthus nivalis agglutinin induce strong immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.06.022

1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 2: lead optimization affording selective, orally bioavailable compounds with potent anti-HIV activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.06.022

1,3,4-Trisubstituted pyrrolidine CCR5 receptor antagonists. Part 1: discovery of the pyrrolidine scaffold and determination of its stereochemical requirements

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.06.022

Analysis of the immunogenic properties of a single-chain polypeptide analogue of the HIV-1 gp120?CD4 complex in transgenic mice that produce human immunoglobulins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.06.022

Alpha-complementation assay for HIV envelope glycoprotein-mediated fusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.06.022

Development of a high-throughput viral-free assay for the measurement of CCR5-mediated HIV/cell fusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.06.022

Development of a Novel High-Throughput Surrogate Assay to Measure HIV Envelope/CCR5/CD4-Mediated Viral/Cell Fusion Using BacMam Baculovirus Technology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.06.022

Recent progress in discovery of small-molecule CCR5 chemokine receptor ligands as HIV-1 inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.06.022

Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.06.022

Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.06.022

Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.06.022

Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.06.022

A trimeric structural subdomain of the HIV-1 transmembrane glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.06.022

CCR5 antagonists: bicyclic isoxazolidines as conformationally constrained N-1-substituted pyrrolidines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.06.022

Aminooxypentane-RANTES induces CCR5 internalization but inhibits recycling: a novel inhibitory mechanism of HIV infectivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.06.022

Novel low molecular weight spirodiketopiperazine derivatives potently inhibit R5 HIV-1 infection through their antagonistic effects on CCR5.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.06.022

Homozygous and heterozygous CCR5-Delta32 genotypes are associated with resistance to HIV infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.06.022

Chloropeptins I and II, novel inhibitors against gp120-CD4 binding from Streptomyces sp.

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.06.022

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.06.022

7 January 2021

Piperazine-based CCR5 antagonists as HIV-1 inhibitors. III: synthesis, antiviral and pharmacokinetic profiles of symmetrical heteroaryl carboxamides

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.06.022

Enhanced expression, native purification, and characterization of CCR5, a principal HIV-1 coreceptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.06.022

Antigenic variation in gp120s from molecular clones of HIV-1 LAI

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.06.022

Co-receptors for HIV-1 entry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.06.022

Anti-human immunodeficiency virus activity of a novel synthetic peptide, T22 ([Tyr-5,12, Lys-7]polyphemusin II): a possible inhibitor of virus-cell fusion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.06.022

Structural requirements for and consequences of an antiviral porphyrin binding to the V3 loop of the human immunodeficiency virus (HIV-1) envelope glycoprotein gp120.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.06.022

Discovery of 4-[(Z)-(4-bromophenyl)- (ethoxyimino)methyl]-1'-[(2,4-dimethyl-3- pyridinyl)carbonyl]-4'-methyl-1,4'- bipiperidine N-oxide (SCH 351125): an orally bioavailable human CCR5 antagonist for the treatment of HIV infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.06.022

Synthesis, SAR, and biological evaluation of oximino-piperidino-piperidine amides. 1. Orally bioavailable CCR5 receptor antagonists with potent anti-HIV activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.06.022

Two mechanisms for human immunodeficiency virus type 1 inhibition by N-terminal modifications of RANTES

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.06.022

Amino-terminally modified RANTES analogues demonstrate differential effects on RANTES receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.06.022

GPCR drug discovery through the exploitation of allosteric drug binding sites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.06.022

A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.06.022

Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.06.022

Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.06.022

HIV-1 entry inhibitors in the side pocket

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.06.022

A luciferase-reporter gene-expressing T-cell line facilitates neutralization and drug-sensitivity assays that use either R5 or X4 strains of human immunodeficiency virus type 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.06.022

Mechanism of HIV-1 Entry into CD4+ T Cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.06.022

SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.06.022

Piperazine-based CCR5 antagonists as HIV-1 inhibitors. II. Discovery of 1-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4- methyl-4-[3(S)-methyl-4-[1(S)-[4-(trifluoromethyl)phenyl]ethyl]-1-piperazinyl]- piperidine N1-oxide (Sch-350634), an orally bioavailabl

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.06.022

Variable sensitivity of CCR5-tropic human immunodeficiency virus type 1 isolates to inhibition by RANTES analogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.06.022

HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.06.022

Analysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.06.022

Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.06.022

1,3,4 Trisubstituted pyrrolidine CCR5 receptor antagonists bearing 4-aminoheterocycle substituted piperidine side chains

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.06.022

CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.06.022

Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.06.022

CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.06.022

The antigenic structure of the HIV gp120 envelope glycoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.06.022

Development of a cell-based enzyme-linked immunosorbent assay for high-throughput screening of HIV type 1 entry inhibitors targeting the coreceptor CXCR4.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.06.022

Inhibitory mechanism of the CXCR4 antagonist T22 against human immunodeficiency virus type 1 infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.06.022

Amino-terminal substitutions in the CCR5 coreceptor impair gp120 binding and human immunodeficiency virus type 1 entry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.06.022

7 January 2021

Fusogenic mechanisms of enveloped-virus glycoproteins analyzed by a novel recombinant vaccinia virus-based assay quantitating cell fusion-dependent reporter gene activation.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.06.022

7 January 2021

CD4-Induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: consequences for virus entry and neutralization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2004.06.022

7 January 2021

10.1016/J.VIROL.2004.06.022

Identifiers

DOI

1 reference

21 September 2017

1 reference